| HealthPartners | Oncology - ado-trastuzumab emtansine (Kadcyla®), | 2026-07-01 |
| HealthPartners | Oncology - ado-trastuzumab emtansine (Kadcyla®), | 2026-07-01 |
| HealthPartners | Oncology - daratumumab and daratumumab | 2026-07-01 |
| HealthPartners | Oncology - isatuximab-irfc (Sarclisa®) – Minnesota | 2026-07-01 |
| HealthPartners | Oncology - long-acting G-CSF | 2026-07-01 |
| HealthPartners | Oncology - long-acting G-CSF – Minnesota Health | 2026-07-01 |
| HealthPartners | Oncology - lutetium lu 177 vipivotide tetraxetan | 2026-07-01 |
| HealthPartners | Oncology - mosunetuzumab-axgb (Lunsumio™) | 2026-07-01 |
| HealthPartners | Oncology - sacituzumab govitecan-hziy (Trodelvy™) – | 2026-07-01 |
| HealthPartners | Oncology - teclistamab-cqyv (Tecvayli®) | 2026-07-01 |